Poly Medicure Ltd (POLYMED) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Poly Medicure is set to report its Q1 FY27 results, marking the first quarter where its recent European acquisitions—PendraCare and Citieffe—will begin contributing to the consolidated top line. Investors will be focused on whether the company's core organic growth can offset recent international headwinds while maintaining its consolidated EBITDA margin guidance of 23–25%.

Poly Medicure Ltd Q1 Results Date and Time

The board meeting is scheduled for August 07, 2026, to approve the unaudited Q1 FY27 standalone and consolidated financial results.

What to expect from Poly Medicure Ltd's Q1 FY27 results

Management has provided FY27 consolidated revenue guidance of Rs. 2,300–2,400 Cr, implying a Q1 run-rate requirement of approximately Rs. 500–530 Cr. While the ~10–11% YoY rupee depreciation against the USD provides a translational tailwind for the ~69% of revenue earned internationally, the critical focus remains on whether organic export growth—which was -3% to -4% in Q4 FY26—has inflected positively. The company's core standalone business continues to target a 25–27% EBITDA margin, though consolidated margins may face near-term dilution due to the integration of PendraCare and Citieffe, which historically operate at 12–14% EBITDA margins. Management maintains a domestic growth target of upwards of 20%, supported by the ongoing import-substitution strategy and a robust pipeline of 20 new products awaiting CE marking in 2026.

Key Things To Watch

Performance vs Guidance Tracking: Tracking Q1 progress against FY27 full-year targets.

• Consolidated Revenue — Rs. 2,300-2,400 Cr for FY27 — Q1 run-rate check ≥ Rs. 500-530 Cr
• Standalone EBITDA Margin — 25-27% for FY27 — Check Q1 margin vs range
• Domestic Growth — >20% for FY27 — Q1 domestic growth rate vs 20%+ target
• CapEx — Rs. 200-225 Cr for FY27 — Q1 spend vs full-year guidance

Strategic Integration and Capex: Updates on recent inorganic initiatives and domestic capacity expansion.

• Integration progress of PendraCare and Medistream SA following late-May 2026 closures
• Phase I commissioning status for Haridwar and Faridabad plants
• US market expansion progress including FDA retesting status for IV catheters

Operating Metric Trajectory: Key performance indicators for the core business.

• Organic international growth trajectory (ex-acquisitions) vs -3% to -4% in Q4 FY26
• Receivable days trend vs Q4 FY26 level of ~103 days
• New sales associate hiring progress toward 100+ target for FY27